MAP2K7 and colorectal carcinoma: Using RAS/BRAF mutant CRC PDOs may help to find out the reasons for unexpected therapeutic effect of MEK/ERK inhibitors, and find biomarkers to predict the therapeutic effect of the inhibitors, and look for new treatment strategy for the refractory CRC.